Skip to main content

EXELIXIS INC

For the period ended Dec 29, 2023. Filed Feb 6, 2024.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Feb 6, 2024

EXEL$71.74+3.1%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized

EXELIXIS, INC.
February 6, 2024By:/s/ MICHAEL M. MORRISSEY
DateMichael M. Morrissey, Ph.D.
President and Chief Executive Officer

POWER OF ATTORNEY

KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints MICHAEL M. MORRISSEY, CHRISTOPHER J. SENNERand JEFFREY J. HESSEKIELand each or any one of them, his or her true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this report on Form 10-K, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or any of them, or their or his or her substitutes or substitute, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed by the following persons on behalf of the Registrant and in the capacities and on the dates indicated.

SignaturesTitleDate
/s/ MICHAEL M. MORRISSEYDirector, President and Chief Executive OfficerFebruary 6, 2024
Michael M. Morrissey, Ph.D.(Principal Executive Officer)
/s/ CHRISTOPHER J. SENNERExecutive Vice President and Chief Financial OfficerFebruary 6, 2024
Christopher J. Senner(Principal Financial and Accounting Officer)
/s/ STELIOS PAPADOPOULOSChairman of the BoardFebruary 6, 2024
Stelios Papadopoulos, Ph.D.
/s/ MARY C. BECKERLEDirectorFebruary 6, 2024
Mary C. Beckerle, Ph.D.
/s/ S. GAIL ECKHARDTDirectorFebruary 6, 2024
S. Gail Eckhardt, M.D.
/s/ MARIA C. FREIREDirectorFebruary 6, 2024
Maria C. Freire, Ph.D.
/s/ ALAN M. GARBERDirectorFebruary 6, 2024
Alan M. Garber, M.D., Ph.D.
SignaturesTitleDate
/s/ TOMAS J. HEYMANDirectorFebruary 6, 2024
Tomas J. Heyman
/s/ DAVID E. JOHNSONDirectorFebruary 6, 2024
David E. Johnson
/s/ ROBERT L. OLIVERDirectorFebruary 6, 2024
Robert L. Oliver, Jr.
/s/ GEORGE POSTEDirectorFebruary 6, 2024
George Poste, DVM, Ph.D., FRS
/s/ JULIE A. SMITHDirectorFebruary 6, 2024
Julie A. Smith
/s/ JACQUELINE WRIGHTDirectorFebruary 6, 2024
Jacqueline Wright
/s/ JACK L. WYSZOMIERSKIDirectorFebruary 6, 2024
Jack L. Wyszomierski
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.